{"id":"NCT00791921","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-11","primaryCompletion":"2010-01","completion":"2010-01","firstPosted":"2008-11-17","resultsPosted":"2012-08-06","lastUpdate":"2012-08-07"},"enrollment":230,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"CDP870","otherNames":[]},{"type":"DRUG","name":"Placebo of CDP870","otherNames":[]}],"arms":[{"label":"CDP870 200mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are to verify the superiority in efficacy (American College of Rheumatology 20%: ACR20) and investigate the pharmacokinetics and safety of CDP870 versus placebo without coadministration of MTX in active RA patients in whom MTX cannot be administrated.","primaryOutcome":{"measure":"American College of Rheumatology 20% (ACR20) Response at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"CDP870 200mg","deltaMin":67.2,"sd":null},{"arm":"Placebo","deltaMin":14.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.05"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["24981319"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":116},"commonTop":["Nasopharyngitis","Rheumatoid arthritis","Pharyngitis","Rash","Eczema"]}}